New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ESRX;TEA From The Last 14 Days
Check below for free stories on ESRX;TEA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
11:43 EDTESRXGilead defended by analysts after recent pullback
Subscribe for More Information
08:41 EDTESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use